ResMed Acquires Noctrix Health for $340 Million
Summary
Angelini Ventures announced that portfolio company Noctrix Health has been acquired by ResMed in a transaction valued at $340 million. Noctrix Health, founded in 2016, developed the Nidra device, the first FDA-authorized non-invasive therapy for moderate-to-severe Restless Legs Syndrome. Angelini Ventures invested in Noctrix Health in 2024 as part of the company's $40 million Series C financing round. ResMed plans to integrate Noctrix's technology into its broader sleep health ecosystem.
Why it matters
This acquisition represents a significant validation of the neurotechnology market's commercial potential and demonstrates strong exit opportunities for investors in clinically differentiated neuromodulation therapies. For patients, integration into ResMed's connected health ecosystem could dramatically expand access to the first non-invasive RLS therapy, addressing a condition that affects millions globally.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial